The New York University Cancer Institute (NYUCI) is seeking funding for its 26th year as an NCI-designated cancer center following a significant re-vitalization of cancer research and treatment activities on the NYU Medical Center campuses that was initiated in 1998. With the recruitment of Dr. Steven Burakoff in 2000 the NYUCI has undergone major expansion. Growth in facilities, faculty recruitment, research productivity, and clinical care has exceeded the benchmarks outlined in strategic plan articulated in the 2002 renewal. During the last funding period, twenty-four faculty in basic, translational and clinical research have been recruited to the NYUCI. Facilities to house research and treatment programs have expanded 400% with the opening the new NYU Clinical Cancer Center and the NYUCI Research Laboratories located within the new Smilow Research Center. Extramural funding has doubled to $64,087,423 (total) in peer reviewed funding and a overall research base of $75,898,561. Funding from the NCI has also doubled and now totals $19,750,445. The Cancer Center Support Grant (CCSG) builds on many unique institutional strengths of this metropolitan hospital center with a highly diverse faculty, staff and patient population. In the current application seven scientific programs are presented for consideration: Cancer Immunology and Immunotherapy, Growth Control, Cancer Stem Cells, Molecular and Environmental Carcinogenesis, Melanoma, Breast Cancer and Genitourinary Cancer. Ten shared resources are supported by the CCSG and two new cores, Vaccine and Cancer Genomics, are presented in the application. The Clinical Trials Office has supported the growth of NYU investigator-initiated studies which now account for 68.7% of all therapeutic accruals. Overall accruals have increased steadily over the past three years from 9.25% in 2004 to 13.3% (projected) in 2006. The NYUCI has fostered an environment that promotes research collaborations and multidisciplinary patient care with 24% of all publications being intra- or interprogrammatic (12% each). The CCSG application continues to be actively supported by the President of NYU, the Dean and CEO of NYU Medical Center, and Hospital and Community leadership who pledge additional resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016087-32
Application #
8232102
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
1996-12-01
Project End
2013-02-28
Budget Start
2012-03-01
Budget End
2013-02-28
Support Year
32
Fiscal Year
2012
Total Cost
$2,512,026
Indirect Cost
$1,030,005
Name
New York University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Xu, Yang; Taylor, Paul; Andrade, Joshua et al. (2018) Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. Cancer Res 78:6539-6548
Gagner, Jean-Pierre; Zagzag, David (2018) Probing Glioblastoma Tissue Heterogeneity with Laser Capture Microdissection. Methods Mol Biol 1741:209-220
Tsay, Jun-Chieh J; Wu, Benjamin G; Badri, Michelle H et al. (2018) Airway Microbiota Is Associated with Upregulation of the PI3K Pathway in Lung Cancer. Am J Respir Crit Care Med 198:1188-1198
Martin, Patricia K; Marchiando, Amanda; Xu, Ruliang et al. (2018) Autophagy proteins suppress protective type I interferon signalling in response to the murine gut microbiota. Nat Microbiol 3:1131-1141
Coux, Rémi-Xavier; Teixeira, Felipe Karam; Lehmann, Ruth (2018) L(3)mbt and the LINT complex safeguard cellular identity in the Drosophila ovary. Development 145:
de la Parra, Columba; Ernlund, Amanda; Alard, Amandine et al. (2018) A widespread alternate form of cap-dependent mRNA translation initiation. Nat Commun 9:3068
Fanok, Melania H; Sun, Amy; Fogli, Laura K et al. (2018) Role of Dysregulated Cytokine Signaling and Bacterial Triggers in the Pathogenesis of Cutaneous T-Cell Lymphoma. J Invest Dermatol 138:1116-1125
Patibandla, Jay R; Fehniger, Julia E; Levine, Douglas A et al. (2018) Small cell cancers of the female genital tract: Molecular and clinical aspects. Gynecol Oncol 149:420-427
Harper, Lamia; Balasubramanian, Divya; Ohneck, Elizabeth A et al. (2018) Staphylococcus aureus Responds to the Central Metabolite Pyruvate To Regulate Virulence. MBio 9:
Berger, Ashton C; Korkut, Anil; Kanchi, Rupa S et al. (2018) A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell 33:690-705.e9

Showing the most recent 10 out of 1170 publications